ABSTRACT Vertebrate cardiac progenitor cells are initially allocated in two distinct domains, the first and second heart fields. It has been demonstrated that first heart field cells give rise to the myocardial cells in the left ventricle and part of the atria, whereas second heart field cells move into the developing heart tube and contribute to the myocardium of the outflow tract and right ventricle and the majority of atria. In this study, we have examined the expression of the mouse Cripto gene and the lineage of Cripto-expressing cells, focusing on its relationship with cardiac myocyte differentiation. The mouse Cripto gene is initially expressed at late head fold (LHF) stages in the cardiac crescent region, known as the first heart field; later in the medial region of the early heart tube, and by embryonic day 8.5, it is localized to the outflow tract. Using a Cripto-LacZ allele, we found that Cripto-expressing progeny cells contribute to the myocardium of the entire outflow tract and right ventricle, as well as to a majority of cells within the left ventricle. In contrast, no Cripto-expressing progeny cells were found in the atria or atrio-ventricular canal. Therefore, Cripto is transiently expressed in early differentiating myocardial cells of the left ventricle, right ventricle and outflow tract between LHF stages and E8.5. Cripto expression is subsequently downregulated as cells undergo further differentiation.
Introduction
The heart is the first functional organ formed during vertebrate embryogenesis. Heart formation involves a series of complex morphogenetic and differentiation events. Late in gastrulation, inductive signals from the anterior endoderm such as BMPs and Fgf8 specify cells in the anterior lateral mesoderm to become cardiac progenitor cells (Alsan and Schultheiss, 2002 , Harvey, 2002 , Ilagan et al., 2006 , Schultheiss et al., 1997 .
Cardiac precursor cells have been ascribed to two heart fields: the first and the second heart field (Laugwitz et al., 2008 , Srivastava, 2006 . Cells of the first heart field are the first to differentiate at cardiac crescent and early heart tube stages, and will give rise to the first heart lineage which largely contributes to the left ventricle and parts of the atria. The second heart field is located dorsal-medial to the first heart field at crescent stages and will give rise to second heart lineages which comprise the outflow tract, right ventricle, and a majority of cell within the atria (Evans et al., 2010 , Laugwitz et al., 2008 , Srivastava, 2006 , Watanabe and Buckingham, 2010 . As development proceeds, cells within the cardiac crescent migrate toward the midline and fuse, forming an anterior-posterior oriented linear heart tube that subsequently undergoes rightward looping (Fishman and Chien, 1997 , Harvey, 2002 , Laugwitz et al., 2008 , Olson and Srivastava, 1996 , Srivastava, 2006 , Srivastava and Olson, 2000 . Following heart tube stages, the heart grows by addition of second heart field cells at both anterior and posterior poles of the heart (Abu- Issa and Kirby, 2008 , Cai et al., 2003 , Kelly et al., 2001 , Laugwitz et al., 2008 , Srivastava, 2006 . The contribution of pharyngeal mesoderm cells to the outflow tract was first demonstrated by dye labeling experiments in chick embryos (Waldo et al., 2001) , and later in mouse embryos by genetic approaches using isl1-Cre, isl-nlacZ, and Mlc1-lacZ mice (Cai et al., 2003 , Kelly et al., 2001 , Sun et al., 2007 . Isl1 mRNA is expressed only in the second heart field and pharyngeal mesoderm (Cai et al., 2003) . Studies with [b-actin-LacZ;isl1-Cre] mouse embryos showed that over 90% of the cells in the outflow tract and the right ventricle are b-galactosidase positive demonstrating the contribution of second heart field cells to the outflow tract and right ventricle (Cai et al., 2003) .
EGF-CFC proteins function as essential co-factors for several transforming growth factor-b (TGF-b) superfamily members such as Nodal, GDFs and Vg-1, to signal through Activin receptors and control various aspects of vertebrate embryogenesis including the formation and patterning of the body plan (Chen et al., 2006 , Cheng et al., 2003 , Gritsman et al., 1999 , Yeo and Whitman, 2001 . The human CRIPTO gene, the founding member of EGF-CFC gene family, was first indentified in human teratocarcinoma cells (Ciccodicola et al., 1989) . Subsequently, the mouse Cripto gene was cloned and shown to be expressed in embryonic mesoderm and developing heart (Dono et al., 1993 , Johnson et al., 1994 , Minchiotti et al., 2000 . Studies with Cripto mutant mouse embryos demonstrated that Cripto plays critical roles in axial patterning, mesoderm and endoderm formation, and ventral midline formation (Chu et al., 2005 , Ding et al., 1998 , Xu et al., 1999 . In addition, loss of Cripto function during ES cell differentiation blocks cardiac myocyte differentiation and promotes neural differentiation (Parisi et al., 2003 , Xu et al., 1999 . Further studies showed that Cripto acts through apelin/APJ to control cardiac lineage in ES differentiation (D'Aniello et al., 2009 ). These ES cell based studies strongly suggested that Cripto may play critical roles in heart development during embryogenesis in vivo. Previous studies on Cripto expression in heart development in vivo were performed mainly before the current two heart field model was formulated. To understand the precise role of Cripto in heart development, it is important to determine the Cripto expression during cardiogenesis in more detail. For example, Cripto was shown previously to express in the outflow tract on E8.5, and it is now known that outflow tract cells are derived from second heart field, and therefore, it is important to find out whether Cripto is expressed at early stage such as crescent stage, if so, it is in the first or second heart field. In addition, cells in the growing heart tube including the outflow tract region are very dynamical, it is critical to know where the Cripto-expressing progeny cells populate. In the present study, we attempted to address these questions, at least to some extent.
Results and Discussion

Expression of Cripto during mouse cardiac development
As shown in Fig. 1 , Cripto mRNA expression was detected at the late head fold stage (LHF), specifically in a region possibly corresponding to the cardiac crescent ( Fig. 1 A,E) . At the 3-4 somite stage, expression was observed in a region consistent with the medial cardiomyocytes in the early heart tube ( Fig. 1 B,F) . Further examination using double in situ hybridization of Cripto with Mlc2a demonstrated that these cells are Mlc2a positive, confirming they are indeed differentiating cardiomyocytes (see section 3 of the results and figure 3 ). At the 6-7 somite stage, Cripto is expressed in the dorsal region of the developing heart tube (Fig. 1 C,G) . On E8.5, when embryos contain 9-10 somites and have undergone cardiac looping, Cripto expression is restricted to outflow tract ( Fig. 1 D,H) , consistent with previous studies showing a restricted Cripto expression in the outflow tract on E8.5 (Dono et al., 1993 , Johnson et al., 1994 , Minchiotti et al., 2000 . At this stage, no Cripto mRNA is observed in pharyngeal mesoderm or foregut endoderm (Fig.1D ). After E8.5, Cripto mRNA is no longer detectable by in situ hybridization.
The progeny of Cripto expressing cells contribute to derivatives of the first heart field and anterior second heart field
To locate the progeny of Cripto-expressing cells, we utilized a Cripto-Lacz allele, in which the LacZ gene is under the control of the endogenous Cripto promoter and recapitulates Cripto expression pattern (Ding et al., 1998) . As b-galactosidase activity is stable, it has been widely used for lineage studies, including the fate of Cripto-expressing cells in axial mesendoderm (Chu et al., 2005 , Ding et al., 1998 . From the early somite stage to embryonic day 8.5 (E8.5), b-galactosidase is present in a broader domain than that observed for Cripto mRNA (Fig. 2 A -D) . Following heart looping, high levels of b-galactosidase activity are observed in the outflow tract and right and left ventricles, whereas Cripto mRNA is restricted to outflow tract only as shown by previous studies (Dono et al., 1993 , Johnson et al., 1994 , Minchiotti et al., 2000 and the present study ( Fig.1 D,H) , indicating that the progeny of Cripto-expressing cells contribute to the ventricular region and to the outflow tract. On E9.5, when Cripto mRNA is no longer expressed in the heart, b-galactosidase activity is retained in the outflow tract and right and left ventricles (Fig. 2 H,I ). However, no b-galactosidase positive cells are present in the atria or atrio-ventricular canal regions 
D,H). Panels (E, F, G and H) are transverse sections corresponding to whole embryos in panels (A, B, C and D), respectively. The expression of Cripto was restricted to myocardial cells, and no expression was found in endocardial cells (G,H). Scale bars represent 200 mm; (A-D) and 50 mm (E-H).
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Cripto in mouse heart development 795 (Fig. 2J ). Serial sections revealed that b-galactosidase positive cells populate the majority of the myocardium in the outflow tract and in the right and left ventricle ventricles at E8.5 and E9.5 (Fig.2 E-G and K-L). It is worth noting that the b-galactosidase staining in the left ventricle is weaker than the staining in the outflow tract and right ventricle (Fig. 2 D,H,I ). Since the left ventricle is derived from the first heart field, the b-galactosidase in the left ventricle is inherited from the cardiac crescent cells on E7.5, whereas the b-galactosidase staining in the outflow tract and right ventricle represent the progeny of Cripto expressing cells from the early heart tube stage to E8.5.
Cripto expressing cells and their progeny are always localized within Mlc2a expression domain
To determine the Cripto expression domain in relation to first and second heart fields at the LHF/cardiac crescent stage, we performed double whole-mount in situ hybridization for Cripto and Mlc2a, an marker for early differentiating myocytes of the cardiac crescent (Cai et al., 2003 , Laugwitz et al., 2008 , and found that Cripto-expressing cells (purple) are exclusively localized within the Mlc2a expression domain (red) in the cardiac crescent (Fig. 3  A-F) . Fig. 3A is a mouse embryo at the LHF stage showing Cripto expression only, and the same embryo was subjected to detection for Mlc2a expression, as shown in Fig. 3B . Cripto-expressing and Mlc2a-expressing cells were co-localized in the crescent region as revealed by section analysis (Fig. 3C) . It is important to note that not all the cells in the crescent were Cripto positive. Instead, only the region immediately adjacent to the second heart field were positive for both Cripto and Mlc2a, whereas crescent cells distal to the second heart field were positive only for Mlc2a expression. At early somite stages when the linear heart tube starts to form, Cripto positive cells were restricted to the medial domain of Mlc2a expression (Fig. 3 D-F) .
We next investigated the location of the progeny of Cripto expressing cells in relation to differentiated myocytes within the early looping heart using b-galactosidase staining in combination with Mlc2a in situ hybridization in Cripto Lacz/Wt embryos at early heart looping stages. Fig. 3G shows a b-galactosidase stained Cripto Lacz/Wt embryo. The same embryo was subjected to Mlc2a in situ hybridization and the strong Mlc2a signal masks the previous b-galactosidase signal (Fig. 3H) . In sections, b-galactosidase signal is also completely masked by signal from Mlc2a mRNA in situ (Fig. 3I) , with the exception of scattered b-galactosidase signals in the endoderm, which are likely to be remnants of early Cripto expression in axial mesoendoderm (Chu et al., 2005) . Therefore, Cripto-expressing cardiac progenitor cells and their progeny are restricted to differentiating myocyte cells of the first and anterior second heart fields.
We next sought to examine the relationship between Criptoexpressing cells and the second heart field by double in situ hybridization for Cripto (in red) and Isl1 (dark purple) at crescent stages, and found that Isl1 mRNA was located dorsal-medial to the Cripto expression domain with no overlap (Fig. 3J) . We also investigated the location of the progeny of Cripto expressing cells in relation to the second heart field by b-galactosidase staining in combination with Isl1 in situ hybridization in Cripto Lacz/Wt embryos at later stages, and found that at linear heart tube stages, Isl1 mRNA was expressed in endoderm and pharyngeal mesenchymal cells distinct from b-gal positive cells (Fig. 3 K,L) .
The foregoing observations are consistent with Cripto being expressed in distinct subpopulations of cardiomyocytes as they first differentiate.
The Cripto expression domain is immediately adjacent to the second heart field. It has been reported previously that this region is positive for Isl1 protein expression, although it is negative for Isl1 mRNA expression (Prall et al., 2007 , Sun et al., 2007 . To test (A-D), 100mm (E-G and K-L), 500 mm (H-J) .
11-12 somite stage (C-G) and E9.5 (H-L). (D,I) frontal views; (C,H) right side view, whereas (J) is left side view. (E, F,K) Cross sections, whereas (G,L) sagittal sections. At early somite stages, b-galactosidase staining positive cells were found in the entire myocardium (arrows in A and B). On E8.25-8.5 with 11-12 somites, intense staining was found in the outflow tract and right ventricle (arrows in C and D) with slightly weak signals in the left ventricle (shot arrow in D). E9.5 embryos showed a similar pattern in the outflow tract, right ventricle and left ventricle regions (arrows in H and I). However, no signal was found in the atria or atrioventricular canal (arrow in J). The majority of myocardial cells in the outflow tract (arrows in E, F, G, K and L), right ventricle (short arrows in K and L) and left ventricle (arrowheads in K and L) were blue and only a few unstained cells were found (arrowheads in F, G,). No signal was found in the pharyngeal mesoderm (arrowheads in C and H). Scale bars represent 200 mm
whether Cripto expressing cells are Isl1 protein positive, we carried out Isl1 immunostaining and Cripto in situ hybridization in adjacent sections and found that Cripto mRNA expression domain is more broad than Isl1 protein expression domain in the heart tube, and the two domains partially overlap in the dorsal portion of the heart tube (see Supplementary Figure) .
In conclusion, the Cripto gene has two phases of expression during mouse cardiac development from the LHF stage to E8.5. At the LHF stage, Cripto is highly expressed in differentiating myocytes in the cardiac crescent that will give rise to the cells of the future left ventricle, but not the atria. From early heart tube stages, cells in the second heart field migrate into the developing heart tube through anterior and posterior poles of the tube and differentiate into myocytes. Previous studies have demonstrated that second heart field cells that migrate through anterior pole will contribute to the myocardial cells in the outflow tract and right ventricle, whereas the cells that move via the posterior pole will contribute to the majority of the atria (Cai et al., 2003 , Evans et al., 2010 , Waldo et al., 2001 . During this process, expression of Cripto mRNA is initially restricted to the medial region of early heart tube, and later (E8.5) to the outflow tract of the heart tube. In contrast, the progeny of Cripto expressing cells populate the right and left ventricles as well as the outflow tract at E8.5 and E9.5. Since Cripto mRNA is not expressed in the right ventricle, it appears that Cripto expression specifically marks differentiating myocytes of the anterior developing heart tube, namely, when second heart field cells are migrating through the anterior pole of the developing heart tube and differentiating to myocytes, these cells express Cripto, but only transiently, as the expression soon disappears once the cells undergo further differentiation. Since Cripto-expressing cells and their progeny cells are not detected in the atrial region, second heart field cells that migrate through the posterior pole of the developing heart tube do not express Cripto as they are differentiating into myocytes.
Materials and Methods
Mouse strains and mutant alleles
The Cripto lacZ allele has been reported previously (Ding et al., 1998) . In this allele, the expression of Lacz gene is controlled by the endogenous Cripto promoter, which recapitulates Cripto expression in vivo. In addition, we performed in situ hybridization using a LacZ gene probe on Cripto lacz/wt embryos and found the expression of LacZ mRNA was identical to the expression of Cripto mRNA (data not shown).
Embryos between E7.5-E8.0 were staged according to Downs and Davis (Downs and Davies, 1993) and by somite number. Embryos from E8.5 to E9.5 were staged by gestation days, the day a plug observed was designated as day 0.5 (E0.5). For any given stage, at least 10 embryos are used for each experiment.
In situ hybridization and b-galactosidase staining
Single probe whole-mount in situ hybridization was carried out as previously described (Shen, 2001) . A plasmid containing full length Cripto cDNA 
A
Cripto in mouse heart development 797 was used to generate the probe for Cripto in situ (Ding et al., 1998) . Probes for Mlc2a and Isl1 were provided by Dr. Sylvia Evans at UCSD (Cai et al., 2003) . Double color whole-mount in situ hybridization protocol was based on (Cai et al., 2003) . Briefly, Digoxigenin and Fluorescein labeled antisense RNA probes were hybridized simultaneously, followed by first blue color reaction using anti-Digoxigenin-AP Fab fragments and NBT/BCIP as the conventional single color in situ hybridization. The second red color detection was visualized by anti-Fluorescein-POD Fab fragments (Roche) and Fast Red. Following the first color development, the embryos were incubated at high temperature followed by treatment with 4% paraformaldehyde and glycine in order to completely inactivate alkaline phosphatase activity. For comparison and documentation, we usually photographed embryos individually before the second color reaction. Whole-mount b-galactosidase staining was performed using standard procedure. Briefly, E7.5-9.5 embryos were fixed in 4% paraformaldehyde at 4 o C for 50-60 minutes and incubated with staining solution (phosphate buffered saline, pH 7.4, 2 mM MgCl 2 , 0.02% Nonidet P -40(v/v), 5mM potassium ferricyanide, 5mM potassium ferrocyanide, and1 mg/ml X-gal) for 4-6 hours at 37 o C. Stained embryos were post-fixed with 10% formalin for at least 24 hours. To combine in situ hybridization with b-galactosidase staining, embryos were first stained for b-galactosidase under RNase free conditions and then fixed overnight in 4% paraformaldehyde at 4 o C followed by washes with PBT (PBS with 0.1% Tween-20) and stored at -20 o C in methanol until processed for in situ hybridization.
